The University of Chicago Header Logo

Connection

Thomas Gajewski to Melanoma

Back to Details
This is a "connection" page, showing publications Thomas Gajewski has written about Melanoma.
Thomas Gajewski
Connection Strength
13.969
Melanoma
  1. Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. Cancer Immunol Res. 2025 Aug 01; 13(8):1284-1302.
    View in: PubMed
    Score: 0.651
  2. PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 04 02; 13(4):547-559.
    View in: PubMed
    Score: 0.636
  3. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.523
  4. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.496
  5. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.447
  6. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
    View in: PubMed
    Score: 0.438
  7. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
    View in: PubMed
    Score: 0.413
  8. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73.
    View in: PubMed
    Score: 0.400
  9. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
    View in: PubMed
    Score: 0.385
  10. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
    View in: PubMed
    Score: 0.368
  11. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768.
    View in: PubMed
    Score: 0.356
  12. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
    View in: PubMed
    Score: 0.332
  13. Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
    View in: PubMed
    Score: 0.321
  14. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116.
    View in: PubMed
    Score: 0.285
  15. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246.
    View in: PubMed
    Score: 0.271
  16. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
    View in: PubMed
    Score: 0.270
  17. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
    View in: PubMed
    Score: 0.249
  18. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42.
    View in: PubMed
    Score: 0.241
  19. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res. 2010 Oct; 23(5):580-1.
    View in: PubMed
    Score: 0.230
  20. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403.
    View in: PubMed
    Score: 0.229
  21. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb; 65(3):509-14.
    View in: PubMed
    Score: 0.214
  22. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009 Apr 01; 69(7):3077-85.
    View in: PubMed
    Score: 0.209
  23. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3.
    View in: PubMed
    Score: 0.205
  24. Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008 Aug; 18(4):289-94.
    View in: PubMed
    Score: 0.200
  25. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61.
    View in: PubMed
    Score: 0.189
  26. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2326s-2330s.
    View in: PubMed
    Score: 0.170
  27. Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance). Cancer Immunol Res. 2026 Mar 04; 14(3):423-433.
    View in: PubMed
    Score: 0.170
  28. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
    View in: PubMed
    Score: 0.169
  29. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5.
    View in: PubMed
    Score: 0.166
  30. Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma. Nat Med. 2025 Jul; 31(7):2385-2396.
    View in: PubMed
    Score: 0.161
  31. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
    View in: PubMed
    Score: 0.151
  32. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.151
  33. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol. 2004 Feb 15; 22(4):580-1.
    View in: PubMed
    Score: 0.146
  34. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
    View in: PubMed
    Score: 0.142
  35. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8.
    View in: PubMed
    Score: 0.140
  36. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 08; 189:112923.
    View in: PubMed
    Score: 0.140
  37. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391.
    View in: PubMed
    Score: 0.133
  38. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.
    View in: PubMed
    Score: 0.133
  39. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278.
    View in: PubMed
    Score: 0.123
  40. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.
    View in: PubMed
    Score: 0.122
  41. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
    View in: PubMed
    Score: 0.121
  42. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s.
    View in: PubMed
    Score: 0.120
  43. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346.
    View in: PubMed
    Score: 0.116
  44. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4.
    View in: PubMed
    Score: 0.112
  45. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
    View in: PubMed
    Score: 0.110
  46. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234.
    View in: PubMed
    Score: 0.107
  47. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 08; 20(8):1083-1097.
    View in: PubMed
    Score: 0.106
  48. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596.
    View in: PubMed
    Score: 0.105
  49. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 03 20; 7(1):80.
    View in: PubMed
    Score: 0.105
  50. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207.
    View in: PubMed
    Score: 0.100
  51. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
    View in: PubMed
    Score: 0.099
  52. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
    View in: PubMed
    Score: 0.095
  53. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
    View in: PubMed
    Score: 0.094
  54. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
    View in: PubMed
    Score: 0.094
  55. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2017 Mar; 143(3):439-445.
    View in: PubMed
    Score: 0.089
  56. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
    View in: PubMed
    Score: 0.089
  57. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402.
    View in: PubMed
    Score: 0.087
  58. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5.
    View in: PubMed
    Score: 0.084
  59. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.083
  60. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374.
    View in: PubMed
    Score: 0.083
  61. Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25.
    View in: PubMed
    Score: 0.081
  62. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
    View in: PubMed
    Score: 0.079
  63. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
    View in: PubMed
    Score: 0.077
  64. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
    View in: PubMed
    Score: 0.077
  65. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440.
    View in: PubMed
    Score: 0.077
  66. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
    View in: PubMed
    Score: 0.076
  67. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18; 311(23):2397-405.
    View in: PubMed
    Score: 0.075
  68. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.071
  69. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.070
  70. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137.
    View in: PubMed
    Score: 0.070
  71. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
    View in: PubMed
    Score: 0.066
  72. Ocular melanoma metastasis to the cervical spine. J Clin Neurosci. 2012 Apr; 19(4):610-1.
    View in: PubMed
    Score: 0.064
  73. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug; 21(8):1712-1717.
    View in: PubMed
    Score: 0.056
  74. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
    View in: PubMed
    Score: 0.052
  75. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27.
    View in: PubMed
    Score: 0.043
  76. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s.
    View in: PubMed
    Score: 0.043
  77. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
    View in: PubMed
    Score: 0.042
  78. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8.
    View in: PubMed
    Score: 0.041
  79. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
    View in: PubMed
    Score: 0.020
  80. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.009
  81. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec; 24(12):3038-43.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.